Joint Research with Koushikai on Preventive Medicine and Immune Parameters
First written in FY2021-Q1. 4 of 6 entries say "Advanced", first in FY2021-Q3. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「As a result, we identified immune parameters whose proportions increased significantly and immune parameters whose proportions decreased significantly before and after immune cell therapy, and are conducting additional clinical research to clarify the significance of these changes.」
The preventive medicine and immune parameter research progressed to additional clinical research to identify immune parameters that change significantly before and after treatment and verify their significance. - FY2023AdvancedAnnual report
「Administration of immune cells to the subjects has been completed, and all immune parameter data have been obtained and are being analyzed.」
The preventive medicine and immune parameter research with 滉志会 progressed to the stage of completing administration, obtaining all data and conducting the analysis. - FY2022AdvancedAnnual report
「Administration of immune cells to the subjects has been completed, and an interim analysis is currently under way.」
The joint research with 滉志会 on preventive medicine and immune parameters progressed, following the start of clinical research, to completion of administration to subjects and the interim analysis stage. - FY2021-Q3AdvancedAnnual report
「The company launched a clinical study under the joint research agreement. It will use the evaluation measures related to cancer prevention, infectious-disease prevention, and healthy longevity obtained through the joint research to advance research toward establishing the usefulness of immune-cell therapy in preventive medicine.」
The joint research with 滉志会 on preventive medicine and immune parameters began clinical research and progressed to the stage of using evaluation measures. - FY2021-Q2RestatedAnnual report
「Seta Clinic Tokyo, a medical institution operated by 滉志会 in Chiyoda-ku, Tokyo, whose director is Goto Shigenori (後藤 重則), is responsible for blood collection, cell therapy, and obtaining medical information, while the company is responsible for cell manufacturing and immunological testing. The company will use the evaluation measures related to cancer prevention, infectious-disease prevention, and healthy longevity obtained through the joint research to advance research toward establishing the usefulness of immune-cell therapy in preventive medicine.」
For the joint research with 滉志会, the company specifically described the division of responsibilities between Seta Clinic Tokyo and the company, how the evaluation measures will be used, and its policy for applying the findings to preventive medicine. - FY2021-Q1First statedAnnual report
「In December 2020, we entered into a joint research agreement with Medical Corporation Kou志会 to explore changes in immune parameters before and after immune cell administration in order to properly evaluate the usefulness of immune cell therapy as preventive medicine and to apply it to preventive medicine. In addition to studying immune parameters relevant to cancer prevention in people at high risk of developing cancer, the research examines immune parameters relating to infectious diseases such as COVID-19 and healthy longevity, with the aim of applying the findings broadly to preventive medicine and regenerative medical product development.」
The Company signed a joint research agreement with Kou志会 in December 2020 to explore immune parameters relating to cancer prevention, infectious diseases and healthy longevity and apply the findings to preventive medicine and regenerative medical product development.